

University of Groningen

Caloric restriction and cellular senescence

Fontana, Luigi; Nehme, Jamil; Demaria, Marco

Published in:
Mechanisms of Ageing and Development

DOI:
[10.1016/j.mad.2018.10.005](https://doi.org/10.1016/j.mad.2018.10.005)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Final author's version (accepted by publisher, after peer review)

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Fontana, L., Nehme, J., & Demaria, M. (2018). Caloric restriction and cellular senescence. *Mechanisms of Ageing and Development*, 176, 19-23. <https://doi.org/10.1016/j.mad.2018.10.005>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Caloric restriction and cellular senescence

Luigi Fontana^{1,2,3,}, Jamil Nehme^{4,5,*}, Marco Demaria⁴*

¹Charles Perkins Centre and Central Clinical School, The University of Sydney, Australia; ²Department of Medicine, Washington University School of Medicine, St. Louis, USA; ³Department of Clinical and Experimental Sciences, Brescia University, Brescia, Italy; ⁴University of Groningen, European Research Institute for the Biology of Aging, University Medical Center Groningen, Groningen, Netherlands; ⁵Lebanese University, Doctoral School of Science and Technology, Hadath, Beirut, Lebanon;

*equal contribution

#correspondence to: Luigi Fontana, luigi.fontana@sydney.edu.au; Marco Demaria, m.demaria@umcg.nl

Cellular senescence

Cellular senescence was originally described as the limited proliferative capacity of cultured human fibroblasts¹. This phenomenon, now termed replicative senescence, is caused by telomere erosion. Currently, it is generally accepted that senescence can be prematurely induced by many different insults, including oxidative stress, genotoxic stress, epigenetic changes, metabolic dysfunction, over activation of oncogenes or loss of some tumor suppressor genes, and mitochondrial dysfunction².

The main defining characteristic of senescence is permanent growth arrest, and p53-p21 and p16^{INK4a} – pRB are the two essential pathways responsible for this replicative arrest³. Interestingly, both p53 and p16^{INK4a} are the most commonly mutated genes in cancer, suggesting that one of the evolutionary advantages of the senescence response is to suppress the development of cancer⁴.

In addition to the growth arrest, which is a necessary but insufficient marker of senescent cells, many features and molecular markers are used for identifying senescence. For instance, a commonly used marker is the senescence-associated beta-galactosidase staining (SA- β gal)⁵. The increase in SA- β gal activity is thought to be a consequence of increased lysosomal mass^{6,7}. Due the fact that there is no universal marker, the combination of many senescence-associated hallmarks is currently used for the unequivocal characterization and identification of senescent cells⁸.

Although p16^{INK4a} is expressed by many but not all senescent cells, it is now generally accepted to be one of the most specific senescence markers *in vivo*^{9,10}. This led to the design of two distinct mouse models where p16^{INK4a}-positive cells can be selectively eliminated^{11,12}. These models contributed much to our understanding about the causal roles of senescent cells in many different processes that include aging, age-related diseases, and wound healing¹¹⁻¹⁸.

Numerous senescence inducers can cause genomic damage that can remain unresolved. As a result, the DNA damage response (DDR) is constantly active because of the chronic persistence of DNA damage foci. Those foci are generally termed DNA-SCARS (DNA segments with chromatin alterations reinforcing senescence)¹⁹. The persistent DDR signaling function as one of the main drivers of the expression of the senescence associated secretory phenotype (SASP)²⁰.

The SASP is a complex mixture of secreted factors that can be divided in 3 main categories: 1) factors binding to receptors (soluble signaling molecules, such as cytokines, chemokines, and growth factors), 2) factors acting directly (matrix metalloproteases, serine proteases and small non-protein components, such as reactive oxygen (ROS) and nitrogen species), and 3) regulatory factors (tissue inhibitors of metalloproteases, the plasminogen activator inhibitor, and insulin-like growth factor binding proteins)²¹.

In addition to secreted factors, senescent cells can also influence their surrounding through juxtacrine NOTCH/JAG1 signaling²² or via intercellular transfer of different molecules through cytoplasmic bridges²³ or exosomes release²⁴. Importantly, some SASP components can reinforce senescence²⁵ and induce senescence in neighboring cells (paracrine senescence)²⁶.

It is clear now that the composition of SASP factors is dependent on the type of cells and senescence inducers²⁷. Moreover, the SASP can be regulated at different levels and it seems that most of the pathways that are important for the establishment of this phenotype converge into activation of the NF- κ B and the C/EBP β pathway²¹. Strikingly, the mechanistic target of rapamycin (mTOR) pathway, an essential player in the aging process, is an important node in SASP regulation²⁸⁻³⁰.

Many age-related diseases, if not all, share a chronic low-grade inflammatory state referred to as inflammaging³¹. Elimination of senescent cells reduces many proinflammatory factors such as IL-6, IL-1 α and TNF- α ¹⁷, suggesting that the SASP is, at least in part, causing this increased inflammatory state in old tissues. Given the fact that senescent cells are present in a small percentage in old tissues³², it is highly plausible that the positive effect seen after senescent cells elimination is a consequence of SASP suppression.

Growing body of evidence has demonstrated the implication of senescence in aging and age-related pathologies. Hence, targeting senescent cells either by eliminating them using “senolytics” or inhibiting the deleterious effect of SASP, might be a promising approach for enhancing healthy longevity³³. Several literature reviews have covered the pharmacological elimination of senescent cells elsewhere³³⁻³⁵.

However, another plausible approach is to avoid the formation of senescent cells by preventing cellular damage, and accumulating data in experimental animal models and humans suggest that caloric restriction (CR) without malnutrition may be a promising intervention in this context.

Calorie restriction

Calorie restriction (CR) with adequate nutrient intake is the most powerful non-genetic intervention for extending healthspan and lifespan in multiple animal models, including yeast, fruit flies, worms, and rodents³⁶. In most strains of rats and mice a reduction of dietary calories by 20 up to 50% results in a substantial extension of both average and maximal lifespan, even if mice with different genotypes respond differently to the same degree of restriction³⁷. Not only these CR animals, supplied with the appropriate amount of calories and nutrients, live significant longer, but many of the typical age-associated chronic diseases are either prevented or delayed. For example, the incidence of cancer, the

leading cause of death in rodents, is drastically reduced in CR animals; similar reductions or slowing down of disease progression have been observed for nephropathy, cardiomyopathy, diabetes, chronic lung diseases, autoimmune diseases and neurodegenerative disease^{36,37}.

Accumulating data indicate that CR extends lifespan also in non-human primates³⁸. In Rhesus monkeys, CR significantly improves metabolic health, prevents obesity, glucose intolerance/type 2 diabetes, and postpones the onset of sarcopenia, hearing loss and atrophy of certain key subcortical regions of the brain, including the caudate and putamen and the left insula (34). Moreover, CR in monkeys reduces morbidity and mortality for cancer, cardiovascular disease and frailty^{39,40}. Indeed, in contrast to the scientifically unsupported opinion that long-term CR promotes frailty⁴¹⁻⁴³, recent data from the Wisconsin CR Primate study clearly show that the levels of weakness, poor endurance, slowness, low physical activity and frailty were significantly lower in the CR than in the ad-libitum fed monkeys⁴⁴.

In humans, calorie restriction with adequate intake of vitamins and minerals causes many of the same physiological, metabolic and molecular adaptations observed in CR animals. For example, moderate CR leads to major improvements in all the classical cardiovascular risk factors, over and above those conferred by weight loss, even when implemented in healthy young and middle-aged non-obese men and women. Interestingly, these cardiometabolic adaptations are coupled with improvements in cardiac and arterial function, including improvements in left ventricular diastolic function and heart rate variability⁴⁵. Like in small mammals, CR in humans causes major modifications of several hormones that are implicated in the pathogenesis of cancer and in the biology of aging⁴⁶. Serum concentrations of insulin, testosterone, estradiol and several inflammatory markers were significantly lower, while IGFBP-1, SHBG, adiponectin and cortisol concentration were higher in people practicing CR group than in controls eating Western diets ad-libitum⁴⁵. Plasma triiodothyronine concentration, and as a consequence average 24- hour, day- time and night- time core body temperature, were also significantly reduced, supporting a strong CR-mediated inhibitory effect on metabolic rate and oxidative stress⁴⁷.

CR-mediated molecular mechanisms promoting health and longevity

The mechanisms mediating the health benefits of CR are not fully understood. Multiple systemic metabolic, neuroendocrine and immunological adaptations coupled with cell-specific molecular mechanisms are involved. For example, calorie restriction without malnutrition exerts a powerful effect in improving insulin sensitivity and in reducing protein glycation, oxidative stress and free radical-induced cellular damage⁴⁸⁻⁵⁰. The CR induced reduction of multiple anabolic hormones and growth factors causes a down-regulation of the nutrient-sensing insulin/IGF signaling network and an activation of FOXO,

which modifies several “longevity genes”⁵¹, including endogenous antioxidant enzymes (e.g. SOD2, catalase), DNA repair (e.g. DDB1) and autophagy (e.g. beclin-1, autophagin-1) genes⁵². Autophagy and mitophagy are important for the removal of dysfunctional organelles, amyloid and other protein aggregates that interfere with normal cell function⁵³. FOXO activation is also a powerful inhibitor of cyclin D, a master regulator of cell cycle progression and cell proliferation. Another major adaptation to CR is the reduction in plasma concentrations of inflammatory cytokines and a modest increase in circulating cortisol that results in a reduction in systemic inflammation together with a protection against aging-associated deterioration in immune function^{54,55}. Increased expression of protein chaperones such as heat shock protein-70 is also important to improve proteostasis, the removal of damaged cellular proteins and cellular stress resistance^{50,56}. As we will discuss later, other molecular effectors that have been shown to mediate the health effects of CR include TOR⁵⁷, AMPK⁵⁸, sirtuins⁵⁹, and NRF2⁶⁰. Energy and amino acids restriction cause an inhibition of mTORC1 activity, which in turn enhances autophagy, improves proteostasis and stem cell function⁶¹. Overexpression of sirtuins (i.e. SIRT1, SIRT3 and SIRT6) improves metabolic homeostasis through histone deacetylation, inhibits NF-κB signaling and increases genomic stability⁵⁹. In addition, activation of AMPK and SIRT1 up-regulates PGC-1α, a key transcriptional factor regulating mitochondrial function, antioxidant defenses, and fatty acid oxidation⁶².

CR and cellular senescence

Different studies have shown that CR reduce senescence markers in different mouse organs and human colon mucosa^{9,63-66}. One of the main inducers of senescence is cellular damage. Therefore, it is highly plausible that CR reduces the generation of senescent cells by preventing damage to occur. CR can protect cellular deterioration in at least two major ways: interfering with the source of damage, for example via decreasing oxidative stress and inflammation, or repairing/eliminating already present damage, for example by increasing autophagy (Figure 1)^{49,50,54}.

An important source of cellular damage is oxidative stress, mainly caused by an accumulation of reactive oxygen species (ROS). Historically, the beneficial effects of CR were thought to be the result of slow metabolism resulting in reduced production of ROS⁶⁷, but it is now known that CR can actively regulate many other defense mechanisms against oxidative stress^{52,68}. Numerous experiments have established that sirtuins are critically required to reduce oxidative stress. In accordance, CR induces the expression of SIRT3, which was shown to play an essential role in reducing oxidative damage and its related pathologies^{69,70}. It is interesting to note that mitochondrial dysfunction caused by SIRT3 downregulation can, in fact, induce senescence⁷¹. Another member of the sirtuin family, SIRT1, was reported to mediate aspects of CR response⁷². Due to the fact that some studies have demonstrated the important role of SIRT1 in regulating oxidative status within the cell⁷³, it is highly possible that SIRT1 mediates its effect

during CR by reducing levels of oxidative stress. These notions suggest that CR might prevent senescence, in part, by upregulating the antioxidant defense program partly through the increase of sirtuins function and in part through up-regulation of FOXO.

Autophagy, a major lysosomal degradation pathway that is activated by CR, might act as an anti-senescence mechanism by clearance of damaged proteins and organelles including damaged mitochondria^{50,74}. Intriguingly, selective elimination of dysfunctional mitochondria by mitophagy alleviate many aspects of the senescence phenotype⁷⁵.

Another mechanism by which CR can prevent senescence is through enhancement of DNA repair mechanisms. Interestingly, CR activates many pathways that can prevent and aid in resolving DNA lesions. For instance, CR reduces age-dependent decline in non-homologous end joining (NHEJ)⁷⁶. In addition, it can improve nucleotide excision repair (NER), increase the fidelity of polymerase alpha and beta, and decrease their age dependent decline^{77,78}. Moreover, CR can also protect DNA by inducing the base excision repair pathway (BER), both in young and aged animals⁷⁹.

It has been shown that CR can regulate longevity pathways that include the insulin/insulin growth factor I signaling (IIS), both in rodents and human. Circulating IGF-1 levels were decreased during CR in rodents⁸⁰, whereas in human the effect was not direct. Long-term CR results in a persistent increase in serum IGFBP-1 leading to a decrease in IGF-1:IGFBP-1 ratio levels, which can probably inhibit IGF-1 signaling by decreasing free IGF-1 in circulation⁸¹. Notably, prolonged exposure of cells to IGF-1 can induce premature senescence through the regulation of SIRT1-p53 pathway⁸². Accordingly, the decrease in IGF-1 activity, as a consequence of CR, might help in preventing premature senescence.

Finally, the mechanistic target of rapamycin (mTOR) is also negatively affected by CR. A large portion of the senescence associated secretory phenotype components is regulated by mTOR²⁸, including factors that can induce secondary senescence⁸³. In addition, mTOR can promote geroconversion, the conversion from a proliferative arrest to irreversible senescence, and mitigation of its activity favors quiescence⁸⁴. For these reasons, CR could also prevent the activation and spread of senescence by inhibiting mTOR.

Conclusion

CR is a well-established intervention for reducing age-associated chronic diseases and enhancing lifespan. In this review, we have summarized some of the mechanisms by which CR exerts its beneficial effects, highlighting their complexity and heterogeneity. However, reduction of cellular damage might well be related, at least in part, to prevention of cellular senescence. In the next few years, it will be key to monitor the effects of long-term CR on cell senescence in various tissues to determine whether there is

any organ-specificity for damage protection. It will be also of high interest to treat animals under CR with senolytic drugs to prove any synergistic effect of lowering cellular damage and eliminating senescent cells. Another important question is whether the absence of senescent cells during CR might trigger side effects – for example promoting longer kinetic of wound healing, a known issue for animals under CR⁸⁵. Finally, similar studies on the prevention of senescent cells should be directed towards alternative and less invasive dietary interventions with anti-aging properties, such as intermittent fasting and/or protein restriction⁸⁶⁻⁸⁸.

Acknowledgements

L.F. is supported by grants from the Bakewell Foundation, the Longer Life Foundation (an RGA/Washington University Partnership), the National Center for Research Resources (UL1 RR024992), and the Italian Federation of Sport Medicine (FMSI).

J.N. is supported by the National Council for Scientific Research-Lebanese University (CNRS-L) scholarship. M.D. is supported by grants from the Dutch Cancer Foundation (KWF).

The author apologizes for the omission of relevant work owing to space constraints.

Competing interests

M.D. is co-founder of Cleara Biotech, a company devoted to develop senolytic interventions. However, he did not receive any compensation from the company related to this work.

Bibliography

1. Hayflick, L. The Limited in Vitro Lifetime of Human Diploid Cell Strains. *Experimental cell research* **37**, 614-636 (1965).
2. McHugh, D. & Gil, J. Senescence and aging: Causes, consequences, and therapeutic avenues. *The Journal of cell biology* **217**, 65-77 (2018).
3. Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol* **8**, 729-740 (2007).
4. Sager, R. Senescence as a mode of tumor suppression. *Environmental health perspectives* **93**, 59-62 (1991).
5. Dimri, G.P., *et al.* A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proceedings of the National Academy of Sciences of the United States of America* **92**, 9363-9367 (1995).
6. Kurz, D.J., Decary, S., Hong, Y. & Erusalimsky, J.D. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. *Journal of cell science* **113** (Pt 20), 3613-3622 (2000).
7. Lee, B.Y., *et al.* Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. *Aging cell* **5**, 187-195 (2006).

- 208 8. Hernandez-Segura, A., Nehme, J. & Demaria, M. Hallmarks of Cellular Senescence. *Trends in cell*
209 *biology* **28**, 436-453 (2018).
- 210 9. Krishnamurthy, J., *et al.* Ink4a/Arf expression is a biomarker of aging. *The Journal of clinical*
211 *investigation* **114**, 1299-1307 (2004).
- 212 10. Burd, C.E., *et al.* Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase
213 model. *Cell* **152**, 340-351 (2013).
- 214 11. Demaria, M., *et al.* An essential role for senescent cells in optimal wound healing through
215 secretion of PDGF-AA. *Dev Cell* **31**, 722-733 (2014).
- 216 12. Baker, D.J., *et al.* Clearance of p16Ink4a-positive senescent cells delays ageing-associated
217 disorders. *Nature* **479**, 232-236 (2011).
- 218 13. Chinta, S.J., *et al.* Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and
219 Contributes to Neuropathology Linked to Parkinson's Disease. *Cell Rep* **22**, 930-940 (2018).
- 220 14. Jeon, O.H., *et al.* Local clearance of senescent cells attenuates the development of post-
221 traumatic osteoarthritis and creates a pro-regenerative environment. *Nat Med* **23**, 775-781
222 (2017).
- 223 15. Demaria, M., *et al.* Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer
224 Relapse. *Cancer Discov* **7**, 165-176 (2017).
- 225 16. Chang, J., *et al.* Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem
226 cells in mice. *Nat Med* **22**, 78-83 (2016).
- 227 17. Baker, D.J., *et al.* Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. *Nature*
228 **530**, 184-189 (2016).
- 229 18. Zhu, Y., *et al.* The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging*
230 *Cell* **14**, 644-658 (2015).
- 231 19. Rodier, F., *et al.* DNA-SCARS: distinct nuclear structures that sustain damage-induced
232 senescence growth arrest and inflammatory cytokine secretion. *Journal of cell science* **124**, 68-
233 81 (2011).
- 234 20. Rodier, F., *et al.* Persistent DNA damage signalling triggers senescence-associated inflammatory
235 cytokine secretion. *Nat Cell Biol* **11**, 973-979 (2009).
- 236 21. Borodkina, A.V., Deryabin, P.I., Giukova, A.A. & Nikolsky, N.N. "Social Life" of Senescent Cells:
237 What Is SASP and Why Study It? *Acta naturae* **10**, 4-14 (2018).
- 238 22. Hoare, M., *et al.* NOTCH1 mediates a switch between two distinct secretomes during
239 senescence. *Nat Cell Biol* **18**, 979-992 (2016).
- 240 23. Biran, A., *et al.* Senescent cells communicate via intercellular protein transfer. *Genes &*
241 *development* **29**, 791-802 (2015).
- 242 24. Lehmann, B.D., *et al.* Senescence-associated exosome release from human prostate cancer cells.
243 *Cancer research* **68**, 7864-7871 (2008).
- 244 25. Acosta, J.C., *et al.* Chemokine signaling via the CXCR2 receptor reinforces senescence. *Cell* **133**,
245 1006-1018 (2008).
- 246 26. Acosta, J.C., *et al.* A complex secretory program orchestrated by the inflammasome controls
247 paracrine senescence. *Nat Cell Biol* **15**, 978-990 (2013).
- 248 27. Hernandez-Segura, A., *et al.* Unmasking Transcriptional Heterogeneity in Senescent Cells. *Curr*
249 *Biol* **27**, 2652-2660 e2654 (2017).
- 250 28. Laberge, R.M., *et al.* mTOR regulates the pro-tumorigenic senescence-associated secretory
251 phenotype by promoting IL1A translation. *Nat Cell Biol* **17**, 1049-1061 (2015).
- 252 29. Herranz, N., *et al.* mTOR regulates MAPKAPK2 translation to control the senescence-associated
253 secretory phenotype. *Nat Cell Biol* **17**, 1205-1217 (2015).
- 254 30. Narita, M., *et al.* Spatial coupling of mTOR and autophagy augments secretory phenotypes.
255 *Science* **332**, 966-970 (2011).

- 256 31. Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution
257 to age-associated diseases. *J Gerontol A Biol Sci Med Sci* **69 Suppl 1**, S4-9 (2014).
- 258 32. Biran, A., *et al.* Quantitative identification of senescent cells in aging and disease. *Aging cell* **16**,
259 661-671 (2017).
- 260 33. Ovadya, Y. & Krizhanovsky, V. Strategies targeting cellular senescence. *J Clin Invest* **128**, 1247-
261 1254 (2018).
- 262 34. Soto-Gamez, A. & Demaria, M. Therapeutic interventions for aging: the case of cellular
263 senescence. *Drug Discov Today* **22**, 786-795 (2017).
- 264 35. Childs, B.G., *et al.* Senescent cells: an emerging target for diseases of ageing. *Nat Rev Drug*
265 *Discov* **16**, 718-735 (2017).
- 266 36. Fontana, L., Partridge, L. & Longo, V.D. Extending healthy life span--from yeast to humans.
267 *Science* **328**, 321-326 (2010).
- 268 37. Mitchell, S.J., *et al.* Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice. *Cell*
269 *Metab* **23**, 1093-1112 (2016).
- 270 38. Mattison, J.A., *et al.* Caloric restriction improves health and survival of rhesus monkeys. *Nature*
271 *communications* **8**, 14063 (2017).
- 272 39. Colman, R.J., *et al.* Caloric restriction reduces age-related and all-cause mortality in rhesus
273 monkeys. *Nature communications* **5**, 3557 (2014).
- 274 40. Mattison, J.A., *et al.* Impact of caloric restriction on health and survival in rhesus monkeys from
275 the NIA study. *Nature* **489**, 318-321 (2012).
- 276 41. Dirks, A.J. & Leeuwenburgh, C. Caloric restriction in humans: potential pitfalls and health
277 concerns. *Mechanisms of ageing and development* **127**, 1-7 (2006).
- 278 42. Miller, S.L. & Wolfe, R.R. The danger of weight loss in the elderly. *The journal of nutrition, health*
279 *& aging* **12**, 487-491 (2008).
- 280 43. Sardeli, A.V., Komatsu, T.R., Mori, M.A., Gaspari, A.F. & Chacon-Mikahil, M.P.T. Resistance
281 Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A
282 Systematic Review and Meta-Analysis. *Nutrients* **10**(2018).
- 283 44. Yamada, Y., *et al.* Caloric Restriction and Healthy Life Span: Frail Phenotype of Nonhuman
284 Primates in the Wisconsin National Primate Research Center Caloric Restriction Study. *The*
285 *journals of gerontology. Series A, Biological sciences and medical sciences* **73**, 273-278 (2018).
- 286 45. Most, J., Tosti, V., Redman, L.M. & Fontana, L. Calorie restriction in humans: An update. *Ageing*
287 *Res Rev* **39**, 36-45 (2017).
- 288 46. Longo, V.D. & Fontana, L. Calorie restriction and cancer prevention: metabolic and molecular
289 mechanisms. *Trends in pharmacological sciences* **31**, 89-98 (2010).
- 290 47. Soare, A., Cangemi, R., Omodei, D., Holloszy, J.O. & Fontana, L. Long-term calorie restriction, but
291 not endurance exercise, lowers core body temperature in humans. *Aging* **3**, 374-379 (2011).
- 292 48. Weiss, E.P., *et al.* Improvements in glucose tolerance and insulin action induced by increasing
293 energy expenditure or decreasing energy intake: a randomized controlled trial. *The American*
294 *journal of clinical nutrition* **84**, 1033-1042 (2006).
- 295 49. Il'yasova, D., *et al.* Effects of 2 years of caloric restriction on oxidative status assessed by urinary
296 F2-isoprostanes: The CALERIE 2 randomized clinical trial. *Aging cell* **17**(2018).
- 297 50. Yang, L., *et al.* Long-Term Calorie Restriction Enhances Cellular Quality-Control Processes in
298 Human Skeletal Muscle. *Cell Rep* **14**, 422-428 (2016).
- 299 51. Webb, A.E. & Brunet, A. FOXO transcription factors: key regulators of cellular quality control.
300 *Trends in biochemical sciences* **39**, 159-169 (2014).
- 301 52. Mercken, E.M., *et al.* Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a
302 younger transcription profile. *Aging cell* **12**, 645-651 (2013).

- 303 53. Cuervo, A.M. Calorie restriction and aging: the ultimate "cleansing diet". *The journals of*
304 *gerontology. Series A, Biological sciences and medical sciences* **63**, 547-549 (2008).
- 305 54. Meydani, S.N., *et al.* Long-term moderate calorie restriction inhibits inflammation without
306 impairing cell-mediated immunity: a randomized controlled trial in non-obese humans. *Aging*
307 *(Albany NY)* **8**, 1416-1431 (2016).
- 308 55. Contreras, N.A., Fontana, L., Tosti, V. & Nikolich-Zugich, J. Calorie restriction induces reversible
309 lymphopenia and lymphoid organ atrophy due to cell redistribution. *GeroScience* **40**, 279-291
310 (2018).
- 311 56. Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell*
312 **153**, 1194-1217 (2013).
- 313 57. Johnson, S.C., Rabinovitch, P.S. & Kaeberlein, M. mTOR is a key modulator of ageing and age-
314 related disease. *Nature* **493**, 338-345 (2013).
- 315 58. Burkewitz, K., Zhang, Y. & Mair, W.B. AMPK at the nexus of energetics and aging. *Cell*
316 *metabolism* **20**, 10-25 (2014).
- 317 59. Guarente, L. Calorie restriction and sirtuins revisited. *Genes & development* **27**, 2072-2085
318 (2013).
- 319 60. Martin-Montalvo, A., Villalba, J.M., Navas, P. & de Cabo, R. NRF2, cancer and calorie restriction.
320 *Oncogene* **30**, 505-520 (2011).
- 321 61. Efeyan, A., Zoncu, R. & Sabatini, D.M. Amino acids and mTORC1: from lysosomes to disease.
322 *Trends in molecular medicine* **18**, 524-533 (2012).
- 323 62. Wu, Z., *et al.* Mechanisms controlling mitochondrial biogenesis and respiration through the
324 thermogenic coactivator PGC-1. *Cell* **98**, 115-124 (1999).
- 325 63. Fontana, L., *et al.* The effects of graded caloric restriction: XII. Comparison of mouse to human
326 impact on cellular senescence in the colon. *Aging cell* **17**, e12746 (2018).
- 327 64. Wang, C., *et al.* Adult-onset, short-term dietary restriction reduces cell senescence in mice.
328 *Aging (Albany NY)* **2**, 555-566 (2010).
- 329 65. Ogrodnik, M., *et al.* Cellular senescence drives age-dependent hepatic steatosis. *Nature*
330 *communications* **8**, 15691 (2017).
- 331 66. Jurk, D., *et al.* Postmitotic neurons develop a p21-dependent senescence-like phenotype driven
332 by a DNA damage response. *Aging cell* **11**, 996-1004 (2012).
- 333 67. Sohal, R.S. & Weindruch, R. Oxidative stress, caloric restriction, and aging. *Science* **273**, 59-63
334 (1996).
- 335 68. Luo, H., Chiang, H.H., Louw, M., Susanto, A. & Chen, D. Nutrient Sensing and the Oxidative Stress
336 Response. *Trends in endocrinology and metabolism: TEM* **28**, 449-460 (2017).
- 337 69. Qiu, X., Brown, K., Hirschey, M.D., Verdin, E. & Chen, D. Calorie restriction reduces oxidative
338 stress by SIRT3-mediated SOD2 activation. *Cell metabolism* **12**, 662-667 (2010).
- 339 70. Someya, S., *et al.* Sirt3 mediates reduction of oxidative damage and prevention of age-related
340 hearing loss under caloric restriction. *Cell* **143**, 802-812 (2010).
- 341 71. Wiley, C.D., *et al.* Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory
342 Phenotype. *Cell Metab* **23**, 303-314 (2016).
- 343 72. Herranz, D. & Serrano, M. SIRT1: recent lessons from mouse models. *Nature reviews. Cancer* **10**,
344 819-823 (2010).
- 345 73. Brunet, A., *et al.* Stress-dependent regulation of FOXO transcription factors by the SIRT1
346 deacetylase. *Science* **303**, 2011-2015 (2004).
- 347 74. Levine, B. & Klionsky, D.J. Development by self-digestion: molecular mechanisms and biological
348 functions of autophagy. *Developmental cell* **6**, 463-477 (2004).
- 349 75. Ito, S., *et al.* PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD
350 pathogenesis. *Autophagy* **11**, 547-559 (2015).

76. Lee, J.E., *et al.* Calorie restriction (CR) reduces age-dependent decline of non-homologous end joining (NHEJ) activity in rat tissues. *Experimental gerontology* **46**, 891-896 (2011).
77. Guo, Z., Heydari, A. & Richardson, A. Nucleotide excision repair of actively transcribed versus nontranscribed DNA in rat hepatocytes: effect of age and dietary restriction. *Experimental cell research* **245**, 228-238 (1998).
78. Linn, S., Kairis, M. & Holliday, R. Decreased fidelity of DNA polymerase activity isolated from aging human fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America* **73**, 2818-2822 (1976).
79. Cabelof, D.C., *et al.* Caloric restriction promotes genomic stability by induction of base excision repair and reversal of its age-related decline. *DNA repair* **2**, 295-307 (2003).
80. SHIMOKAWA, I., *et al.* Life span extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction. *The FASEB Journal* **17**, 1108-1109 (2003).
81. Fontana, L., *et al.* Effects of 2-year calorie restriction on circulating levels of IGF-1, IGF-binding proteins and cortisol in nonobese men and women: a randomized clinical trial. *Aging cell* **15**, 22-27 (2016).
82. Tran, D., *et al.* Insulin-like growth factor-1 regulates the SIRT1-p53 pathway in cellular senescence. *Aging cell* **13**, 669-678 (2014).
83. Nelson, G., Kucheryavenko, O., Wordsworth, J. & von Zglinicki, T. The senescent bystander effect is caused by ROS-activated NF-kappaB signalling. *Mechanisms of ageing and development* **170**, 30-36 (2018).
84. Leontieva, O.V., *et al.* Hypoxia suppresses conversion from proliferative arrest to cellular senescence. *Proc Natl Acad Sci U S A* **109**, 13314-13318 (2012).
85. Hunt, N.D., *et al.* Effect of calorie restriction and refeeding on skin wound healing in the rat. *Age (Dordr)* **34**, 1453-1458 (2012).
86. Patterson, R.E. & Sears, D.D. Metabolic Effects of Intermittent Fasting. *Annual review of nutrition* **37**, 371-393 (2017).
87. Mattson, M.P., *et al.* Meal frequency and timing in health and disease. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 16647-16653 (2014).
88. Simpson, S.J., *et al.* Dietary protein, aging and nutritional geometry. *Ageing research reviews* **39**, 78-86 (2017).